Leqvio and Metformin Interaction: What Patients and Clinicians Need to Know

Is There an Interaction Between Leqvio and Metformin?

No interaction is expected. The inclisiran label states that no formal clinical drug interaction studies were conducted, that inclisiran is not a substrate, inhibitor or inducer of cytochrome P450 enzymes or transporters, and it lists no specific interacting drug [1].

The metformin label's interaction table names carbonic anhydrase inhibitors such as topiramate, zonisamide, acetazolamide and dichlorphenamide, and drugs that reduce metformin clearance through OCT2 or MATE transporters: ranolazine, vandetanib, dolutegravir and cimetidine [2]. Inclisiran does not appear on that list [2].

Why the Two Drugs Are Unlikely to Affect Each Other

Inclisiran acts inside liver cells

Inclisiran is a small interfering RNA carrying a GalNAc (N-acetylgalactosamine) tag that helps liver cells take it up. Through RNA interference it directs catalytic breakdown of PCSK9 messenger RNA, which leaves more LDL receptors on the liver cell surface to clear LDL cholesterol [1]. The molecule itself is metabolized by nucleases into shorter nucleotides; it is not a CYP450 or transporter substrate, and about 16% is cleared by the kidney [1].

Its plasma life is short. After a 284 mg subcutaneous dose, concentrations peak at about 4 hours, the terminal half-life is about 9 hours, and the drug is undetectable by 24 to 48 hours, while the LDL cholesterol effect lasts months [1]. In a population pharmacokinetic analysis, inclisiran did not clinically significantly change atorvastatin or rosuvastatin concentrations [1].

Metformin is a renally cleared biguanide

The metformin label describes it as decreasing hepatic glucose production, decreasing intestinal glucose absorption and improving insulin sensitivity [2]. It is not metabolized, is negligibly bound to plasma proteins, and is cleared by the kidneys [2].

HealthRX.com offers metformin by prescription.

Renal Function: Where the Two Labels Meet

Metformin carries a boxed warning for lactic acidosis. The label says to check eGFR before starting and at least yearly. It is contraindicated at an eGFR below 30 mL/min/1.73 m2, starting is not recommended at 30 to 45, and if eGFR later falls below 45 the label says to reassess benefit and risk [2]. The label also says to stop metformin at the time of, or before, an iodinated contrast procedure in patients with eGFR 30 to 60, a history of liver disease, alcoholism or heart failure, or when intra-arterial contrast is used, then re-check eGFR 48 hours later and restart only if renal function is stable [2].

The Leqvio label says no dose adjustment is needed for mild, moderate or severe renal impairment, and that it has not been studied in end-stage renal disease [1]. Renal impairment raised inclisiran exposure, with peak concentration 2.3- to 3.3-fold higher and total exposure 1.6- to 2.3-fold higher, but LDL cholesterol lowering was similar across renal function groups [1]. That is a statement about inclisiran on its own, not about an interaction with metformin.

What Did the ORION Trials Test?

The two pivotal adult trials gave inclisiran on top of maximally tolerated statin therapy: ORION-10 randomized 1,561 adults with atherosclerotic cardiovascular disease and ORION-11 randomized 1,617 with ASCVD or a risk equivalent [3]. At day 510, the placebo-corrected LDL cholesterol reduction was 52.3% in ORION-10 and 49.9% in ORION-11 [3]. Adverse events were generally similar to placebo except for more injection-site events [3]. Neither trial was designed as a drug-interaction study.

Metformin Safety Points, Independent of Leqvio

The metformin boxed warning says lactic acidosis often begins subtly, with malaise, muscle aches, breathing difficulty, drowsiness or abdominal pain. Named risk factors include renal impairment, age 65 or older, contrast studies, surgery and other procedures, hypoxic states such as acute heart failure, excessive alcohol intake, hepatic impairment and certain drugs. If it is suspected, the label says to stop metformin and treat in hospital, with prompt hemodialysis recommended [2]. The label also reports subnormal vitamin B12 in about 7% of patients in 29-week trials and says to measure vitamin B12 at 2 to 3 year intervals [2].

For inclisiran, the label's only warning is hypersensitivity: anaphylaxis and angioedema have been reported after marketing, and the label says patients should seek prompt medical attention for symptoms [1].

The Practical Answer

Known: neither label identifies a shared metabolic or transporter step, inclisiran's label lists no interacting drug, and metformin's interaction table does not include inclisiran [1][2]. Not studied: the Leqvio label reports no formal clinical drug interaction studies, so the pair has not been tested directly [1].